1. 1555O_PRMagnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe. (23rd October 2018) Authors: Hwang, T; Vokinger, K; Tibau, A; Gyawali, B; Naci, H; Franklin, J M; Beall, R; Kesselheim, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1563PDMagnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval. (23rd October 2018) Authors: Borrell Puy, M; Molto Valiente, C; Vokinger, K; Hwang, T; Ocana Fernandez, A; Templeton, A J; Seruga, B; Gich Saladich, I; Barnadas, A; Amir, E; Tibau, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗